Artwork

Content provided by Third Wave. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Third Wave or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Rick Doblin, Ph.D. - MDMA, MAPS & the FDA: What Went Wrong?

1:04:41
 
Share
 

Manage episode 486355935 series 2826791
Content provided by Third Wave. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Third Wave or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes back Rick Doblin, Ph.D., Founder and President of MAPS (Multidisciplinary Association for Psychedelic Studies), for a deeply personal and visionary conversation on the recent FDA rejection of MDMA-assisted therapy.

Find full show notes and links here: https://thethirdwave.co/podcast/episode-306/?ref=278

Rick opens up about the painful setbacks, internal missteps, and his own process of recovery and renewed hope. He explains why this isn’t the end—but a critical turning point for psychedelic medicine.

Rick and Paul unpack the nuances of drug plus therapy, exploring why context, integration, and culture matter as much as pharmacology. They reflect on the future of MAPS, the psychedelic renaissance beyond FDA approval, and how business, politics, and spirituality intersect with healing. The episode also explores Rick’s enduring belief in public benefit models, global collaboration, and the potential of a spiritualized humanity.

Rick Doblin, Ph.D., is the Founder and President of MAPS. He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, and has spent nearly four decades advancing the safe and legal use of psychedelics and marijuana through science, education, and advocacy.

Highlights:

  • The cost of MAPS' quiet period
  • Why MDMA therapy was rejected by FDA
  • Pharma vs. therapy: What’s best for patients?
  • Drug-only treatments vs. integrated therapy
  • Ibogaine’s role in brain healing and PTSD
  • MAPS’ path forward: Phase 4 vs. Phase 3
  • What the Dutch got right about MDMA
  • Spiritualized humanity and self-transcendence
  • The global impact of MAPS’ work
  • Business, love, and psychedelic ethics

Want to attend this year’s Psychedelic Science 2025 Conference? For our community: Use code THIRDWAVE15 for 15% off registration. Learn more and register at psychedelicscience.org — See you there!

Episode Links

Episode Sponsors:

  continue reading

307 episodes

Artwork
iconShare
 
Manage episode 486355935 series 2826791
Content provided by Third Wave. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Third Wave or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes back Rick Doblin, Ph.D., Founder and President of MAPS (Multidisciplinary Association for Psychedelic Studies), for a deeply personal and visionary conversation on the recent FDA rejection of MDMA-assisted therapy.

Find full show notes and links here: https://thethirdwave.co/podcast/episode-306/?ref=278

Rick opens up about the painful setbacks, internal missteps, and his own process of recovery and renewed hope. He explains why this isn’t the end—but a critical turning point for psychedelic medicine.

Rick and Paul unpack the nuances of drug plus therapy, exploring why context, integration, and culture matter as much as pharmacology. They reflect on the future of MAPS, the psychedelic renaissance beyond FDA approval, and how business, politics, and spirituality intersect with healing. The episode also explores Rick’s enduring belief in public benefit models, global collaboration, and the potential of a spiritualized humanity.

Rick Doblin, Ph.D., is the Founder and President of MAPS. He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, and has spent nearly four decades advancing the safe and legal use of psychedelics and marijuana through science, education, and advocacy.

Highlights:

  • The cost of MAPS' quiet period
  • Why MDMA therapy was rejected by FDA
  • Pharma vs. therapy: What’s best for patients?
  • Drug-only treatments vs. integrated therapy
  • Ibogaine’s role in brain healing and PTSD
  • MAPS’ path forward: Phase 4 vs. Phase 3
  • What the Dutch got right about MDMA
  • Spiritualized humanity and self-transcendence
  • The global impact of MAPS’ work
  • Business, love, and psychedelic ethics

Want to attend this year’s Psychedelic Science 2025 Conference? For our community: Use code THIRDWAVE15 for 15% off registration. Learn more and register at psychedelicscience.org — See you there!

Episode Links

Episode Sponsors:

  continue reading

307 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play